SPD489 (Lisdexamfetamine dimesylate)
SPD489-344
Phase 3 small_molecule completed
Quick answer
SPD489 (Lisdexamfetamine dimesylate) for Binge Eating Disorder is a Phase 3 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 2 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Binge Eating Disorder
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed